Keren Pelen, Patrick Boissy, Karina Lebel, Alexandra Mayhew, Marla K Beauchamp, Lauren E Griffith, Megan E O'Connell, Sarah N Hilmer, Marie-Laure Baroud, Caroline Sirois, Frank Moriarty, Jean-Philippe Turcotte, Lisa Kouladjian O'Donnell, Kathryn Nicholson, Benoit Cossette
{"title":"Association between anticholinergic and sedative medications and physical functioning: data from the Canadian longitudinal study on aging (CLSA).","authors":"Keren Pelen, Patrick Boissy, Karina Lebel, Alexandra Mayhew, Marla K Beauchamp, Lauren E Griffith, Megan E O'Connell, Sarah N Hilmer, Marie-Laure Baroud, Caroline Sirois, Frank Moriarty, Jean-Philippe Turcotte, Lisa Kouladjian O'Donnell, Kathryn Nicholson, Benoit Cossette","doi":"10.1007/s00228-026-04068-w","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>The cumulative use of anticholinergic and sedative medications has been associated with lower physical function in older adults. This study aimed to identify which physical function attributes are most impacted in subgroups aged 45-64 and 65-85 years.</p><p><strong>Methods: </strong>Baseline data from 30,097 community-living Canadians in the Canadian Longitudinal Study on Aging were analysed using a cross-sectional design. Anticholinergic and sedative medications use was quantified using the Drug Burden Index (DBI). Physical functioning was measured via the timed 4-meter walk, Timed Up and Go (TUG), single leg balance, chair rise and grip strength. Physical functioning profiles were generated using latent profile analysis of the five tests. Associations between DBI scores and physical functioning were assessed through linear regression and multinomial logistic regression.</p><p><strong>Results: </strong>The mean age of participants was 63.0, 50.9% were female, 18.3% had a DBI score 0 < DBI < 1 and 8.7% a DBI score ≥ 1. Adjusted regression models showed the greatest reduction in standardized scores for the TUG test among participants with DBI ≥ 1 (β: -6.05; -6.77 to - 5.33) relative to DBI = 0. Latent profile analysis indicated that the two profiles with the poorest physical functioning were associated with higher odds of exposure to 0 < DBI < 1 and DBI ≥ 1, whereas the profile reflecting the best functioning was associated with reduced odds of exposure to DBI ≥ 1. Associations of similar magnitude were observed across age strata (45-64 and 65-85 years).</p><p><strong>Conclusion: </strong>Cumulative anticholinergic and sedative medication burden was inversely associated with physical functioning. These findings were consistent across middle-aged and older adults.</p>","PeriodicalId":11857,"journal":{"name":"European Journal of Clinical Pharmacology","volume":"82 6","pages":""},"PeriodicalIF":2.7000,"publicationDate":"2026-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Clinical Pharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00228-026-04068-w","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
Abstract
Purpose: The cumulative use of anticholinergic and sedative medications has been associated with lower physical function in older adults. This study aimed to identify which physical function attributes are most impacted in subgroups aged 45-64 and 65-85 years.
Methods: Baseline data from 30,097 community-living Canadians in the Canadian Longitudinal Study on Aging were analysed using a cross-sectional design. Anticholinergic and sedative medications use was quantified using the Drug Burden Index (DBI). Physical functioning was measured via the timed 4-meter walk, Timed Up and Go (TUG), single leg balance, chair rise and grip strength. Physical functioning profiles were generated using latent profile analysis of the five tests. Associations between DBI scores and physical functioning were assessed through linear regression and multinomial logistic regression.
Results: The mean age of participants was 63.0, 50.9% were female, 18.3% had a DBI score 0 < DBI < 1 and 8.7% a DBI score ≥ 1. Adjusted regression models showed the greatest reduction in standardized scores for the TUG test among participants with DBI ≥ 1 (β: -6.05; -6.77 to - 5.33) relative to DBI = 0. Latent profile analysis indicated that the two profiles with the poorest physical functioning were associated with higher odds of exposure to 0 < DBI < 1 and DBI ≥ 1, whereas the profile reflecting the best functioning was associated with reduced odds of exposure to DBI ≥ 1. Associations of similar magnitude were observed across age strata (45-64 and 65-85 years).
Conclusion: Cumulative anticholinergic and sedative medication burden was inversely associated with physical functioning. These findings were consistent across middle-aged and older adults.
期刊介绍:
The European Journal of Clinical Pharmacology publishes original papers on all aspects of clinical pharmacology and drug therapy in humans. Manuscripts are welcomed on the following topics: therapeutic trials, pharmacokinetics/pharmacodynamics, pharmacogenetics, drug metabolism, adverse drug reactions, drug interactions, all aspects of drug development, development relating to teaching in clinical pharmacology, pharmacoepidemiology, and matters relating to the rational prescribing and safe use of drugs. Methodological contributions relevant to these topics are also welcomed.
Data from animal experiments are accepted only in the context of original data in man reported in the same paper. EJCP will only consider manuscripts describing the frequency of allelic variants in different populations if this information is linked to functional data or new interesting variants. Highly relevant differences in frequency with a major impact in drug therapy for the respective population may be submitted as a letter to the editor.
Straightforward phase I pharmacokinetic or pharmacodynamic studies as parts of new drug development will only be considered for publication if the paper involves
-a compound that is interesting and new in some basic or fundamental way, or
-methods that are original in some basic sense, or
-a highly unexpected outcome, or
-conclusions that are scientifically novel in some basic or fundamental sense.